The Center for Systems Immunology represents a cutting-edge research area of growing importance. It develops modern trends in research (systems biology approaches, big data, informatics), and it addresses one of the areas of the School of Medicine's strategic plan, Immunity. Moreover, its goals intersect with other important strategic research aims, including immunotherapy for cancer and other diseases.
Immune monitoring has emerged as a critical component of any therapeutic intervention that targets the immune system. The Center for Systems Immunology is defining states of the immune system that enable therapeutic responses, revealing how and when to use immunotherapy, who will benefit, and how to design approaches to enable non-responders to become responsive to immune-based therapies.
- Cancer: anti-PD-1, Canakinumab (anti-IL-1beta), cell-based therapies and cytokine-based therapies
- Autoimmunity and inflammatory disorders: Humira and analogs; Canakinumab and other antibody-based and cell-based interventions
- Cardiovascular diseases (CVD): Cantos study highlighted the role of Canakinumab in decreasing incidence and severity of CVD
- Opportunities for collaborations and funding in tuberculosis, malaria, hepatitis C virus (HCV) and hepatitis B virus (HBV)
- Therapeutic vaccines and cytokine based therapies